Systems and methods are provided for a non-invasive high resolution pressure pulse waveform measurement system. The system may include a blood pressure cuff, an air pump to inflate the blood pressure cuff to specific pressure levels, high resolution pressure sensors configured to perform high sensitivity signal acquisition at a specified pressure level, high range pressure sensors configured to measure an absolute reference for the signal and to calibrate the signal, pneumatic tubing connecting the air pump and sensors with the cuff, and a hydrodynamic filter configured as an input to a reference port of the high resolution pressure sensor. The hydrodynamic filter may be configured to transmit only mean pressure by attenuating a selected frequency range of the signal.
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
Systems and methods disclosed herein relate to the detection of irregular particles in a blood flow based on a determined relative speed of a particle suspended in a blood flow and/or other properties of a particle suspended in a blood flow including a particle's relative position within a blood vessel and a particles tendency to cluster with other particles suspended in a blood flow. Based on a determined relative speed and/or other relevant factors, the properties of irregular particles may also be measured, including the size, shape, and frequency of irregular particles in a blood flow. Machine learning techniques may be employed to determine patterns for the behavior of irregular particles suspended in a blood flow. These patterns may correspond to particular health risks and conditions.
Disclosed herein include methods, compositions, and kits suitable for use in vaccination. There are provided, in some embodiments, nucleic acid compositions (e.g., mRNA vaccine, DNA vaccine) comprising a polynucleotide encoding a fusion protein. The fusion protein can comprise an antigenic polypeptide (AP) and an endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD). A plurality of fusion proteins can be capable of self-assembling into an enveloped nanoparticle (ENP) secreted from a cell in which the fusion proteins are expressed. There are provided, in some embodiments, populations of ENPs.
Disclosed herein is a composition for linked amplification tethered with exponential radiance for signal amplification. Also disclosed herein, is a kit for linked amplification tethered with exponential radiance for signal amplification. Also disclosed herein, is a method linked amplification tethered with exponential radiance for signal amplification.
A system of a multi-rotor aircraft that capitalizes on the advantages of fixed wing elements combined with rotary wing structures. The fixed wing elements can help to generate lift once the aircraft is airborne and can thus reduce the need for larger lifting rotors which can allow for longer flight times and distances. Additionally, the systems disclosed herein take advantage of a partial in-wing configuration with a number of rotors to reduce the overall footprint of the vehicle while maintaining the flight efficiency that comes with combining features of fixed and rotary wing elements, and increasing operator safety by shrouding rotating parts. The unique configurations allow for a decoupling of the pitch, yaw and roll authority to reduce the complexity in control systems and improve the flight efficiency of the aircraft. Additional configurations implement the use of smaller thrust rotors that can be used to generate thrust as well as control yaw and thus counteract any remaining unbalanced torque.
A system and method for controlling a multi-rotor aircraft that implements the unconventional use of different sized rotors. The different sized rotors than the main rotors tend to generate an unbalanced torque and pitch on the aircraft that effectively decouples the pitch and yaw control from the main rotors. The atypical design tends to lend itself to improved control capabilities and simplified control systems. Additional configurations implement the use of smaller thrust rotors that can be used to generate thrust as well as control yaw and thus counteract any remaining unbalanced torque from the odd auxiliary rotor.
A network of high-resolution cameras for monitoring and controlling a drone within a specific operational environment such that the latency time for communication between the cameras and drone is less than that of human controlled drones. The drone can communication drone health data to the network of cameras where such information can be combined with visual image data of the drone to determine the appropriate flight path of the drone within the operational environment. The drone can then subsequently be controlled by the network of cameras by maintaining a constant visual image and flight control data of the drone as it operates within the environment.
Disclosed herein include circuits, compositions, nucleic acids, populations, systems, and methods enabling single circuits to generate multiple molecularly and functionally distinct states that are each stable across multiple cell division cycles. Synthetic circuits provided herein can stably exist in multiple distinct states characterized by differences in the concentrations and expression levels of its components. In the absence of changes to the external environment, each of these states can be stable. In some embodiments, transcription factors provided herein activate when dimerized, and show much weaker activity as monomers. In some embodiments, each transcription factor homodimer activates expression of its own gene. In some embodiments, transcription factors can form mixed heterodimers with one another that do not strongly activate any genes in the circuit. Different embodiments of the synthetic circuits provided herein can use different numbers of transcription factors to produce a growing number of stable states.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Disclosed herein is a membrane-based, in-gel loop-mediated isothermal amplification (LAMP) system, kit and method for detection of a target microorganism in a sample suspected of containing the microorganism. LAMP reagents, a lysing agent and a hydrogel are placed together on a filter membrane loaded with a pre-filtered sample. The hydrogel polymerizes over a short time to immobilize any target DNA/RNA particles on the membrane. The system may include a compact, portable device that integrates heat incubation and fluorescence illumination, and also a cloud-based smartphone image analysis application for quantitative results interpretation. If target DNA/RNA are present in the sample, fluorescent amplicons are produced as a result of LAMP reaction. The target microorganisms are detected by visually detecting the presence or absence of the amplicons. The method may be employed for rapid and inexpensive point-of-use (POU) absolute quantification of SARS-CoV-2 in environmental water or wastewater samples with high sensitivity.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
11.
MULTIVALENT CARRIERS AND RELATED VACCINE COMPOSITIONS
Disclosed herein include multivalent carriers comprising a plurality of heterologous coronavirus proteins antigens derived from different coronaviruses. The multivalent carriers herein described can elicit heterologous binding and neutralization properties against coronaviruses that differ from the coronaviruses from which the coronavirus antigens are derived to produce the multivalent carriers. Also provided herein include vaccine compositions comprising the multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications.
Disclosed are electrochemical systems that include an electrodialyzer and a vapor-fed CO2 reduction (CO2R) cell to capture and convert CO2 from ocean water. The electrodialyzer includes a stack of bipolar membrane electrodialysis (BPMED) cells between end electrodes. The electrodialzyer incorporates monovalent cation exchange membranes (M-CEMs) that prevent the transfer of multivalent cations between adjacent cell compartments, allowing continuous recirculation of electrolytes and solutions, and thus providing a safer and more scaling-free electrodialysis system. In some embodiments, the electrodialyzer may be configured to replace the water-splitting reaction at end electrodes with one-electron, reversible redox couples in solution at the electrodes. As a result, in the entire electrodialyzer stack, there is no bond-making, bond-breaking reactions and there is no gas generation, which significantly simplifies the cell design and improves operational safety. The systems provide a unique technological pathway for CO2 capture and conversion from ocean water with only electrochemical processes.
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
13.
ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with tropisms showing increased viral transduction in the CNS. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating CNS-related diseases and conditions.
Systems and methods for measuring flow velocity of a fluid mixture in a lateral section of an oil/gas well are presented. The flow velocity is measured by tracking movement of particles and/or features in the fluid mixture via visible and/or infrared imaging sensors of a camera-based flow sensor (250). According to another aspect, the imaging sensors detect back-reflected light by the particles and/or features, the light emitted by illuminators (250b) in the visible and/ or infrared spectrum. According to yet another aspect, the particles are quantum dot illuminators injected into the fluid mixture, the flow velocity based on a time-of-flight of the quantum dots. The camera-based flow sensor may be rotatable to measure flow velocities at different angular positions of a pipe, rotation provided by rotation of an element of a mobile vessel to which the flow sensor is rigidly coupled.
E21B 47/11 - Locating fluid leaks, intrusions or movements using radioactivity
E21B 47/01 - Devices for supporting measuring instruments on drill bits, pipes, rods or wirelines; Protecting measuring instruments in boreholes against heat, shock, pressure or the like
G01P 5/20 - Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring the time taken by the fluid to traverse a fixed distance using particles entrained by a fluid stream
15.
ANALYSIS OF TARGET MOLECULES WITHIN A SAMPLE VIA HYBRIDIZATION CHAIN REACTION
Methods of analysis of a sample using hybridization chain reaction (HCR) are provided herein. Some embodiments involve one, two, or all three of the following aspects: 1) repeated signal detection, 2) overlapping binding sites, and 3) catalytic reporter deposition (CARD). Compositions and kits relating to these are also provided. Some embodiments encompass a method for repeated signal detection with reporter-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more reporters), detecting one or more signals from one or more reporters. In some embodiments, a probe unit comprises two or more HCR fractional initiator probes, wherein an HCR fractional initiator probe comprises a target-binding region and a fractional initiator, wherein the target-binding regions within a probe unit are configured to bind to overlapping or non-overlapping binding sites on the target, and wherein the fractional initiators on the probes within each probe unit are configured to bind to overlapping or non-overlapping binding sites on an HCR hairpin. Some embodiments encompass a method for HCR-mediated catalytic reporter deposition (CARD) for signal detection with hapten-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more haptens), providing one or more anti-haptens labeled with one or more reporter entities, wherein the reporter entity is an enzyme that mediates CARD, providing one or more CARD-substrates leading to deposition of one or more reporters, and detecting one or more signals from one or more reporters.
A composition sensor (250) for measuring the composition of fluid mixtures (such as, for example, oil, water, and gas composition of an oil well) is presented. A system for gathering information about physical properties in a lateral section of a well, such as an oil well, is presented. The system comprises a mobile vessel (200) with the composition sensor (250) attached. The composition sensor (250) includes a plurality of high-brightness emission sources having respective spectrally narrow wavelength emission bands in the near-infrared region, e.g. in the region between 1400-1800 nm. The wavelength emission bands may overlap absorption wavelength bands of the composition. The wavelength emission bands are time multiplexed, and may be wavelength multiplexed, prior to emission through the fluid mixture. The composition sensor (250) includes a pair of opposing arms separated by a distance that defines a length of a measurement flow channel of the composition sensor. The arms may rotate to measure composition at different angular position of a pipe in a lateral section of an oil well.
E21B 49/00 - Testing the nature of borehole walls; Formation testing; Methods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells
G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/85 - Investigating moving fluids or granular solids
Provided are an apparatus and method for blood pressure measurement using an electroacoustic transducer in combination with a piezoelectric ultrasonic transducer. The apparatus and method can provide continuous, noninvasive blood pressure monitoring.
A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers
A61B 5/0225 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers the pressure being controlled by electric signals, e.g. derived from Korotkoff sounds
A61B 5/023 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skin; Ophthaldynamometers the pressure transducers comprising a liquid column
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
Aspects of the invention include a method of producing a cement material comprising step of: first reacting a calcium-bearing starting material with a first acid to produce an aqueous first calcium salt; second reacting the aqueous first calcium salt with a second acid to produce a solid second calcium salt; wherein the second acid is different from the first acid and the second calcium salt is different from the first calcium salt; and thermally treating the second calcium salt to produce a first cement material. Preferably, but not necessarily, during the second reacting step, reaction between the first calcium salt and the second acid regenerates the first acid.
This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4433 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/527 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Provided are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain and the liver. Therapeutic and biomedical research applications of the rAAVs are also described, including without limitation methods of discovering rAAVs using a multiplexed Cre recombination-based AAV targeted evolution (M- CREATE) method, and methods of treating various diseases and conditions by rAAV-mediated transgene therapy.
The present disclosure is directed to the integration of direct air capture of carbon dioxide with thermochemical water splitting, the latter optionally driven by solar energy. The disclosure is also directed to a process comprising extracting carbon dioxide from an air stream by contacting the air-stream with an alkali metal ion-transition metal oxide of empirical formula AxMO2 (0.1 < x ? 1), where A represents the alkali metal ion comprising sodium ion, potassium ion, or a combination thereof and M comprises iron, manganese, or a combination thereof to form a transition metal composition comprising an oxidized ion extracted-transition metal oxide.
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
25.
SURFACE-IMMOBILIZED BISTABLE POLYNUCLEOTIDE DEVICES FOR THE SENSING AND QUANTIFICATION OF MOLECULAR EVENTS
Bistable devices are constructed using a polynucleotide platform for sensing molecular events such as binding or conformational changes of target molecules. Uses include measurement of target concentration, measuring the effect of environmental condition (such as heat, light, or pH) on the target, or screening a library for molecules that bind the target or modulate its biological function. Devices comprise three regions: a top lid, bottom lid, and flexible linker or hinge between them. A device has an open configuration in which the top and bottom lid are separated, and a closed configuration they are bound close together. Binding domains or variations of the target molecule are fixed to a device so that when the molecular event occurs, the device switches from open to closed, or vice versa, which generates a signal. Optimal device design is determined by the signal modality (optical or electronic) used to measure closure of surface-immobilized devices
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
27.
SYSTEMS, DEVICES, AND METHODS RELATING TO THE MANUFACTURE OF IMPLANTABLE PROSTHETIC VALVES
Improved prosthetic valves, their methods of manufacture, and systems and devices for manufacturing the valves are described. The prosthetic valves can be configured for transcatheter implantation. The prosthetic valves can have artificial leaflets. The prosthetic valves can be manufactured in numerous ways, such as by polymeric dipping processes and/or electrospinning. Sponge-like polymers for valves and other medical devices are also disclosed.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Switzerland)
Inventor
Witte, Owen N.
Mclaughlin Witte, Jami
Ribas, Antoni
Yang, Lili
Bethune, Michael T.
Cebon, Jonathan
Woods, Katherine
Knights, Ashley J.
Baltimore, David
Abstract
Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
C07K 14/085 - Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain, and lung. The rAAV compositions described herein also have tropisms showing decreased specificity and decreased efficiency of viral transduction in an off-target cell type, for e.g., the liver. The rAAV compositions described herein encapsidate a transgene, such a therapeutic nucleic acid. Upon systemic delivery to a subject, the rAAV is capable of increased specificity and increased transduction of the transgene in a target cell-type, as compared to a parental or reference AAV.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Grubbs, Robert H.
Schwartz, Daniel M.
Abstract
Disclosed herein include methods, kits, formulations, and compositions for increasing choroidal or retinal perfusion or promoting non-leaking or minimally-leaking choroidal or retinal revascularization in a subject in need thereof. An effective amount of an angiogenesis factor (e.g., a pro-angiogenic factor and/or a vascular maturation factor) can be administered to the subject.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
The present application discloses nanoparticles carrying therapeutic agents, including chemotherapeutic agents, and targeting ligands suitable for delivering these therapeutic agents through the blood brain barrier and methods of using these patients on those patients in need of such treatment.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
35.
EYE TREATMENT DEVICE HAVINGA THERAPEUTIC LIQUID STORAGE CHAMBER AND A REPLENISHMENT CHAMBER
An eye treatment apparatus is described. The apparatus includes an annular body that has a hollow optical zone in its center. An inner perimeter of the annular body surrounds the optical zone. The inner perimeter has a diameter that corresponds to a diameter of the eye's cornea. An outer perimeter of the annular body has a diameter such that the annular body can extend to underneath the eye lid in an open eye position when the eye treatment apparatus is in operation. In this way, the apparatus can be worn on the eye, where the hollow optical zone substantially corresponds to the cornea and does not interfere with the field of vision. The annular body also includes a storage chamber that stores therapeutic liquid for an eye. An outlet is coupled with the storage chamber such that, in operation, the therapeutic liquid can be dispensed to the eye.
A61F 9/00 - Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
36.
FABRICATION AND DESIGN OF COMPOSITES WITH ARCHITECTED LAYERS
In an aspect, a composite material system comprises: a structure having an architected three-dimensional geometry; wherein said three-dimensional geometry is monolithic and deterministic; and a matrix phase; wherein said matrix phase at least partially infiltrates said structure. In some embodiments, the three-dimensional geometry is a nano- or micro- architected three-dimensional geometry.
In an aspect, provided herein are methods for producing sulfuric acid and hydrogen gas, the methods comprising steps of: providing sulfur dioxide formed by thermal conversion of a sulfur-containing species; electrochemically oxidizing said sulfur dioxide to sulfuric acid in the presence of water; and electrochemically forming hydrogen gas via a reduction reaction. In some embodiments, the methods comprise a step of thermally converting said sulfur-containing species to said sulfur dioxide. Systems configured to perform these methods are also disclosed herein. Also provided herein are methods and systems for producing sulfuric acid and hydrogen gas by electrochemically forming the sulfuric acid and the hydrogen gas in a mixture comprising a sulfur material, a supporting acid, and water. Also provided herein are methods and systems for producing a cement material.
H01M 8/0656 - Combination of fuel cells with means for production of reactants or for treatment of residues with means for production of gaseous reactants by electrochemical means
C01B 17/54 - Preparation of sulfur dioxide by burning elemental sulfur
C04B 2/10 - Preheating, burning, calcining or cooling
The present disclosure is directed at methods of forming an N-Si silyl bond, the method comprising contacting an organic substrate comprising an aromatic amine having at least one N- H bond with a mixture comprising of (a) at least one hydrosilane or hydrosiloxane and (b) at least one hydroxide or alkoxide, under conditions sufficient to form the N-Si bond. The disclosure is further directed to the compositions involved in these methods and the products that result therefrom.
The present invention relates to methods of treating bacterial infections and cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound provided herein. Also provided are methods of inhibiting dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of any of the compounds or compositions described herein.
C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Improved prosthetic heart valves, their methods of manufacture, and systems and devices for manufacturing the valves are described. The prosthetic heart valves can be configured for transcatheter implantation. The prosthetic heart valves can have artificial leaflets. The prosthetic heart valves can be manufactured in numerous ways, such as by polymeric dipping processes.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
WIRELESS VECTOR KINEMATIC SENSING OF LINEAR AND ANGULAR, VELOCITY AND ACCELERATION, AND POSITION AND ORIENTATION VIA WEAKLY-COUPLED QUASISTATIC MAGNETIC FIELDS
Range and orientation of a transmitter and a receiver are found by detecting the magnetoquasistatic field couplings between coils at the transmitter and receiver. Sum functions and ratio functions are calculated for each of the unique magnetoquasistatic field couplings between the transmitter and the receiver. The sum and ratio functions are inverted to determine the drift-free range and orientation. Linear and angular velocity and acceleration are calculated by applying a filter to reduce noise, and then taking the corresponding derivatives.
G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinations; Position-fixing by co-ordinating two or more distance determinations using radio waves
G01C 21/16 - Navigation; Navigational instruments not provided for in groups by using measurement of speed or acceleration executed aboard the object being navigated; Dead reckoning by integrating acceleration or speed, i.e. inertial navigation
42.
MULTIPLEX LABELING OF MOLECULES BY SEQUENTIAL HYBRIDIZATION BARCODING WITH RAPID SWITCHING AND REHYBRIDZATION OF PROBES
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. Through sequential barcoding, the present invention provides methods for high-throughput profiling of a large number of targets, such as transcripts and/or DNA loci. In some embodiments, nucleic acid probes include a signal moiety connected with a binding sequence via a cleavable linker.
Cascaded metasurfaces can control the phase, amplitude and polarization of an electromagnetic beam, shaping it in three dimensional configuration not achievable with other methods. Each cascaded metasurface has dielectric or metallic scatterers arranged in a period array. The shape of the scatterers determines the three dimensional configuration of the output beam and is determined with iterative calculations through computational simulations.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
44.
RUGGEDIZED BUOYANT MEMORY MODULES FOR DATA LOGGING AND DELIVERY SYSTEM USING FLUID FLOW IN OIL AND GAS WELLS
Systems and methods for delivering detailed information about physical properties, including inflow data, in a downhole of a well to the surface without the need of providing cabling to the downhole are presented. Such information can be based on data captured by sensors placed within the downhole of the well, and subsequently stored into memory of ruggedized buoyant memory modules (RBMMs) that are physically injected into the fluid flow of the well. The RBMMs use the flow of the fluid inside of the well to deliver the data to a location where the data can be extracted. Data stored in the RBMMs can be extracted either directly from the RBMMs or remotely via, for example, a wireless interface.
E21B 47/12 - Means for transmitting measuring-signals or control signals from the well to the surface, or from the surface to the well, e.g. for logging while drilling
E21B 43/30 - Specific pattern of wells, e.g. optimizing the spacing of wells
E21B 47/01 - Devices for supporting measuring instruments on drill bits, pipes, rods or wirelines; Protecting measuring instruments in boreholes against heat, shock, pressure or the like
Systems and methods relate to arranging atoms into 1D and/or 2D arrays; exciting the atoms into Rydberg states and evolving the array of atoms, for example, using laser manipulation techniques and high-fidelity laser systems described herein; and observing the resulting final state. In addition, refinements can be made, such as providing high fidelity and coherent control of the assembled array of atoms. Exemplary problems can be solved using the systems and methods for arrangement and control of atoms.
The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially- induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 39/06 - Free radical scavengers or antioxidants
47.
BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOF
Novel monolithic cyclical reflective spatial heterodyne spectrometers (CRSHS) are presented. Monolithic CRSHS in accordance with the invention have a single frame wherein a flat mirror, roof mirror, and symmetric grating are affixed. The invention contains only fixed parts; the flat mirror, roof mirror, and symmetric grating do not move in relation to the frame. Compared to conventional CRSHS known in the art, the present invention enables much smaller and lighter CRSHS, requires less time and skill for maintenance, and is a better economic option. The disclosed invention may include fixed field-widening optical elements or a fiber-fed assembly.
An enhanced stethoscope device and method for operating the enhanced stethoscope are provided. The enhanced stethoscope device generally operates by providing stethoscope sensors, ultrasonic sensors, and other sensors to obtain a series of measurements about a subject. The series of measurements may be correlated, such as by machine learning, to extract clinically relevant information. Also described are systems and methods for ultrasonic beamsteering by interference of an audio signal with an ultrasonic signal.
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. Pre-designed barcodes are associated specific molecular targets through sequential hybridization experiments. A pseudo¬ color based barcoding scheme is developed to overcome limitations in the previous generation of the technology such as lack of visual signals that can be associated with the probes or small internal within cell when carrying out in situ experiments.. The current method can be applied to both in vitro and in situ analysis. According to the method, each barcoding round comprises multiple serial hybridizations where a small number of colored signals (that are associated with probes) are used in each hybridization experiment within a serial hybridization round. Images from each serial hybridization experiment within the same serial hybridization round are combined to form a composite image for each barcoding round. In each barcoding round, the same set of molecular targets are analyzed. After all barcoding rounds are completed, associated of the barcode with these molecular targets is completed.
The present disclosure relates to methods and compositions involving HCR reactions that involve initiators that are split into two or more parts. Effective HCR is dependent upon two or more of these split initiators being brought into proximity (e.g., via binding events mediated by a target) such that a full initiator is formed that is capable of triggering HCR signal amplification.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present invention is directed to compositions for silylating organic substrates containing C-H or O-H bonds, especially heteroaromatic substrates. The compositions are derived from the preconditioning of mixtures of hydrosilanes or organodisilanes with bases, including metal hydroxide and metal alkoxide bases. In some embodiments, the preconditioning results in the formation of reactive silicon hydride species.
Features for rechargeable lithium ion batteries, the batteries optionally employing vertically aligned carbon nanotube scaffolding, are described. Methods of manufacture and a solid polymer electrolyte are described for 3-dimensional battery architectures using the vertically aligned carbon nanotubes. Poly(ethylene)oxide bis(azide) and graphene poly(lactic acid) composite coatings are also described for use in such batteries or others.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0561 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes the electrolyte being constituted of inorganic materials only
H01G 11/56 - Solid electrolytes, e.g. gels; Additives therein
54.
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVS)
Disclosed herein are peptide sequences capable of directing adeno-associated viruses (AAV) to target specific environments, for example the nervous system and the heart, in a subject. Also disclosed are AAVs having non-naturally occurring capsid proteins comprising the disclosed peptide sequences, and methods of using the AAVs to treat diseases.
Described herein are associative polymers capable of controlling a physical and/or chemical property of non-polar compositions that can be used when the non-polar composition is in a flow, and related compositions, methods and systems. Associative polymers herein described have a non-polar backbone with a longest span having a molecular weight that remains substantially unchanged under the flow conditions and functional groups presented at ends of the non-polar backbone, with a number of the functional groups presented at the ends of the non-polar backbone formed by associative functional groups capable of undergoing an associative interaction with another associative functional group with an association constant (k) such that the strength of each associative interaction is less than the strength of a covalent bond between atoms and in particular less than the strength of a covalent bond between backbone atoms.
C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons
C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
C10L 1/06 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons for spark ignition
Compositions and methods for isolating patient -derived antigen-specific T cells include an antigen complex having a polynucleotide barcoded nanoparticle sorting agent complexed with a peptide-loaded streptavidin major histocompatability complex (MHC) tetramer, the barcoding technology allowing for high fidelity screening of a library of the antigen complexes to readily isolate and identify antigen-specific T cells.
The present invention includes novel compounds and compositions including heteroaromatic Silicon-Fluoride-Acceptors, which are useful for PET scanning. The present invention further includes a novel method of 18F imaging for PET scanning, the method comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In one embodiment the invention is practiced in the form of a kit.
This invention provides efficient and scalable enantioselective methods that yield 2-alkyl-2-allylcycloalkyanone compounds with quaternary stereogenic centers. Methods include the method for the preparation of a compound of formula (I), comprising treating a compound of formula (II) or (III), with a palladium (II) catalyst under alkylation conditions.
C07C 49/303 - Saturated compounds containing keto groups bound to rings to a six-membered ring
C07C 49/307 - Saturated compounds containing keto groups bound to rings to a seven- to twelve-membered ring
C07D 211/70 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Disclosed herein are methods and devices for rapid assessment of whether a microorganism present in a sample is susceptible or resistant to a treatment.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
60.
COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut micro biota signature characteristic of an adult. The bacterial species can include Bacleroides (e.g., B.fragilis, B. thetaiomtaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecaiis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
61.
COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiomlaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E.faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.
The present invention describes chemical systems and methods for silylating aromatic organic substrates, said system or method comprising or consisting essentially of a mixture of (a) at least one organosilane and (b) at least one strong base, the definition of strong base now also including hydroxide, especially KOH, said system being preferably, but not necessarily substantially free of a transition-metal compound, and said methods comprising contacting a quantity of the organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate; wherein said system is substantially free of a transition-metal compound.
C07D 333/50 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
65.
METHOD OF DELIVERING THERAPEUTICS AND IMAGING AGENTS BY NANOPARTICLES THAT CROSS THE BLOOD BRAIN BARRIER
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. In some embodiments, through sequential barcoding, the present invention provides methods for high-throughput profiling of a large number of targets, such as transcripts and/or DNA loci.
C12Q 1/6816 - Hybridisation assays characterised by the detection means
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 70/00 - Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or barcodes
Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Described herein are associative polymers capable of controlling one or more physical and/or chemical properties of non-polar compositions and related compositions, methods and systems. The non-polar composition comprises a host composition having a dielectric constant equal to or less than about 5, and at least one associative polymer which is soluble in the host composition in a concentration between from about 0.1c* to about 10c* and comprises a linear, branched, or hyperbranched polymer backbone having at least two ends and a functional group presented at two or more ends of the at least two ends of the backbone, and wherein the linear, branched, or hyperbranched polymer backbone is substantially soluble in a non-polar composition, and the functional group is capable of undergoing an associative interaction with another functional group with an association constant (k) of from 0.1<1ogiok< 1 8
C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
C08F 265/00 - Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group
C08F 290/00 - Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
C08G 83/00 - Macromolecular compounds not provided for in groups
C08L 51/00 - Compositions of graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
69.
CROSSLINKED POLYMER ELECTROLYTE FORMED FROM TELECHELIC PRECURSOR POLYMERS
A composite electrolyte can include a crosslinked polymer formed from telechelic precursor polymers having at least two photoactivatable end functional groups and a molecular weight before crosslinking of between about 1,000 and 1,000,000 Daltons (Da); and a lithium (Li) salt. Electrochemical cells and batteries including such electrolytes are also disclosed, along with various methods of manufacture.
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV -1) has led to the death of at least 25 million people worldwide.
Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.
A sensor with an inner enclosure, an outer enclosure and a first layer between an outer surface of the inner enclosure and an inner surface of the outer enclosure is described. The sensor further includes an energy harvesting tool and an internal source of power. The energy harvesting tool is configured to harvest mechanical and/or thermal energy and/or sunlight from ambient resources and store the harvested energy in the internal source of power.
The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Burdick, Joel W.
Tai, Yu-Chong
Naber, John F.
Keynton, Robert S.
Edgerton, Victor Reggie
Roy, Roland R.
Gerasimenko, Yury
Harkema, Susan J.
Hodes, Jonathan
Angeli, Claudia A.
Nandra, Mandheerej S.
Desautels, Thomas Anthony
Upchurch, Steven L.
Jackson, Douglas J.
Abstract
A neurostimulator device for use with groups (e.g., more than four groups) of electrodes. The neurostimulator may include a stimulation assembly configured to deliver different stimulation to each of the groups. The neurostimulator may also include at least one processor configured to direct the stimulation assembly to deliver stimulation to the groups. The stimulation delivered to at least one of the groups may include one or more waveform shapes other than a square or rectangular wave shape. The processor may receive data from one or more sensors and use that data to modify the stimulation delivered. The neurostimulator may be configured to communicate with an external computing device. The neurostimulator may send data to and/or receive data and/or instructions from the computing device. The computing device may use information collected by one or more sensors to at least partially determine stimulation parameters to communicate to the neurostimulator.
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Nandra, Mandheerej S.
Edgerton, Victor Reggie
Roy, Roland R.
Gerasimenko, Yury
Tai, Yu-Chong
Angeli, Claudia A.
Burdick, Joel W.
Rodger, Damien Craig
Fong, Andy
Lavrov, Igor
Harkema, Susan J.
Abstract
An implantable electrode array assembly configured to apply electrical stimulation to the spinal cord. A substantially electrically nonconductive layer of the device has a first portion positionable alongside the spinal cord that includes a plurality of first openings. The layer has a second portion that includes a plurality of second openings. Electrodes and traces are positioned inside a peripheral portion of a body portion of the device and alongside the layer. At least one of the first openings is adjacent each of the electrodes to provide a pathway through which the electrode may provide electrical stimulation to the spinal cord. At least one of the second openings is adjacent each of the traces to provide a pathway through which the trace may receive electrical stimulation. At least one trace is connected to each electrode and configured to conduct electrical stimulation received by the trace(s) to the electrode
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61N 1/18 - Applying electric currents by contact electrodes
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
78.
HIGH DENSITY EPIDURAL STIMULATION FOR FACILITATION OF LOCOMOTION, POSTURE, VOLUNTARY MOVEMENT, AND RECOVERY OF AUTONOMIC, SEXUAL, VASOMOTOR, AND COGNITIVE FUNCTION AFTER NEUROLOGICAL INJURY
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
Inventor
Gerasimenko, Yury
Burdick, Joel
Hodes, Jonathan
Tai, Yu-Chong
Angeli, Claudia A.
Edgerton, Victor Reggie
Roy, Roland R.
Harkema, Susan J.
Nandra, Mandheerej S.
Desautels, Thomas Anthony
Abstract
Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and/or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and/or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and/or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
A61H 1/00 - Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus Bacteroides.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventor
Puget, Pierre
Myers, Edward B.
Roukes, Michael L.
Abstract
A system for analyzing a gas mixture, including at least one chromatography column (4), means (2) for injecting said mixture into said column (4), and means (6) for detecting the compound(s) fonning the gas mixture, the detection means (6) including at least one detector of the nanosensor type at the outlet of the column and a detector of the nanosensor type in the column, capable of detecting the passage of the compounds. It is then possible to detennine the velocity of each of the compounds within the system.
The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
C07H 19/20 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
The present invention is generally provides recombinant microorganisms comprising engineered metabolic pathways capable of producing C3-05 alcohols under aerobic and anaerobic conditions. The invention further provides ketol-acid reductoisomerase enzymes which have been mutated or modified to increase their NADH- dependent activity or to switch the cofactor preference from NADPH to NADH and are expressed in the modified microorganisms. In addition, the invention provides isobutyraldehyde dehydrogenase enzymes expressed in modified microorganisms. Also provided are methods of producing beneficial metabolites under aerobic and anaerobic conditions by contacting a suitable substrate with the modified microorganisms of the present invention.
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Methods for the preparation of saturated imidazolinium salts and related compounds that comprises reaction of formamidines with compounds such as dihaioethane and an optional base are disclosed. Alternatively, the imidazoünium salts and related compounds can be prepared in a one-step process without purification of the formamidine reactant. These methods make it possible to obtain numerous imidazolinium salts and related compounds under solvent-free reaction conditions and in excellent yields.
C07D 233/06 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
84.
ARRAYS COMPRISING A PLURALITY OF WELLS, EACH WELL RELEASABLY ATTACHED TO A PATTERNED PLURALITY OF DIFFERENT ANTIBODIES
The disclosure provides an array for the multiplexed analysis of a plurality of biomolecules, wherein each well provides a distinct signature of at least one cell or its cellular components. Exemplary arrays comprise a solid substrate comprising a surface and a plurality of primary antibodies attached thereto in a pattern. The plurality of primary antibodies bind different cellular components. Between 3 and 50 different primary antibodies are attached to the solid surface in the pattern. When a polydimethylsiloxane mold comprising a plurality of wells is releasably coupled with the solid substrate, the plurality of wells are oriented to intersect with the pattern of attached primary antibodies and each well is exposed to the pattern of attached primary antibodies. The selective binding of each primary antibody and its target biomolecule is labeled by a detectable secondary antibody. The resultant pattern of detectable secondary antibodies comprises the distinct signature of each well.
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (Fig. IA). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
88.
METHOD AND APPARATUS FOR A BRAGG GRATING TUNABLE FILTER
The present invention relates to tunable filters. More specifically, the present invention pertains to a method and apparatus that allows tuning of a wavelength over a large optical band. The disclosed system and method allows an arbitrary wavelength selection of an incoming beam of light. The disclosed system and method may be used in imaging systems like telescopes or microscopes, or for point sources like laser or optical fibers. Further, in the case of optical fibers, it may be used as an add/drop filter.
A functionalized photocurable perfluoropolyether is used as a material for fabricating a solvent-resitant microfluidic device. Such solvent~ resistant microfluidic devices can be used to control the flow of small amounts of a fluid, such as an organic solvent, and to perform microscale chemical reactions that are not amenable to other polymer-based microfluidic devices.
C08J 5/00 - Manufacture of articles or shaped materials containing macromolecular substances
B01D 15/08 - Selective adsorption, e.g. chromatography
B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
C08G 65/00 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
C08G 85/00 - General processes for preparing compounds provided for in this subclass
G01N 31/00 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroups; Apparatus specially adapted for such methods
patents
